ArticlePediatric rheumatology online journal2026
Juvenile Behçet's disease 2014-2024: multicenter study in Colombia.
Article in Pediatric rheumatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionJuvenile Behçet's disease (JBD) is a rare multisystem inflammatory disorder that primarily affects the oral and genital mucosa, as well as vessels of any caliber. Between 4% and 26% of Behçet's disease cases begin before the age of 16. JBD remains underreported, with only 55 cases documented in Colombia in 2022. Its aetiology is uncertain, with possible infectious and genetic triggers. The wide range of clinical variability often leads to delayed diagnosis and treatment, increasing the risk of serious complications such as thrombosis and neurological damage. MATERIALS AND
methodsA multicenter longitudinal study with retrospective data collection was conducted in patients under 18 years of age who met international diagnostic criteria for JBD between 2014 and 2024 in three Colombian cities: Cali, Bogotá, and Pereira. Clinical and paraclinical data were extracted from medical records and analysed via IBM SPSS Statistics v29 to obtain descriptive statistics and frequency distributions. RESULTS AND DISCUSSION: Fifteen patients were included, with a female predominance (60%). The mean age at symptom onset was 6.1 years, with a mean age at diagnosis of 11.8 years, revealing a diagnostic delay of 5.7 years. The most common manifestations were recurrent oral aphthosis (100%), genital ulcers (73.3%), arthralgia (60%), and neurological (40%) and vascular (20%) involvement-mainly venous thrombosis. The pathergy test was positive in 44.4% of patients, and viral antigens were detected in 46.7%. All patients received colchicine and corticosteroids; 86.7% required additional immunosuppressive therapy, and two patients were treated with biologics.
conclusionJuvenile Behçet's disease in Colombia presents heterogeneous clinical presentations, with a high prevalence of mucocutaneous, musculoskeletal, and neurological involvement. A significant delay in diagnosis was observed, highlighting the need for increased clinical awareness and suspicion. Colchicine and corticosteroids are generally effective, although most patients require immunosuppressive agents, and some require biologic therapy. These findings emphasize the importance of timely diagnosis and individualized treatment strategies to reduce morbidity in affected children.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.